The putative tumor suppressor CDKN1C is an imprinted gene at 11p15.5, a well-known imprinted region often deleted in tumors. The absence of somatic mutations and the frequent diminished expression in tumors would suggest that CDKN1C expression is regulated epigenetically. It has been, however, controversial whether the diminution is caused by imprinting disruption of the CDKN1C/LIT1 domain or by promoter hypermethylation of CDKN1C itself. To clarify this, we investigated the CpG methylation index of the CDKN1C promoter and the differentially methylated region of the LIT1 CpG island (differentially methylated region (DMR)-LIT1), an imprinting control region of the domain, and CDKN1C expression in esophageal cancer cell lines. CDKN1C expression was diminished in 10 of 17 lines and statistically correlated with the loss of methylation at DMR-LIT1 in all but three. However, there was no statistical correlation between CDKN1C promoter MI and CDKN1C expression. Furthermore, loss of CpG methylation was associated with loss of histone H3 lysine 9 (H3K9) methylation at DMR-LIT1. Histone modifications at CDKN1C promoter were not correlated with CDKN1C expression. The data suggested that the diminished CDKN1C expression is associated with the loss of methylation of CpG and H3K9 at DMR-LIT1, not by its own promoter CpG methylation, and is involved in esophageal cancer, implying that DMR-LIT1 epigenetically regulates CDKN1C expression not through histone modifications at CDKN1C promoter, but through that of DMR-LIT1.
Introduction

CDKN1C (p57
KIP2
) is considered to be a tumor suppressor because it maps to 11p15.5, where it has shown frequent loss of heterozygosity in various tumors (Henry et al., 1989; Bepler and Garcia-Blanco, 1994; Shibagaki et al., 1994; Baffa et al., 1996) . It encodes a cyclin-dependent kinase inhibitor (Lee et al., 1995; Matsuoka et al., 1995) , suppresses myc/RAS-mediated transformation (Watanabe et al., 1998) , and causes the cancer-predisposing Beckwith-Wiedemann syndrome (BWS) by gene mutation (Hatada et al., 1996b) . While no somatic mutation in tumors has been found (Tokino et al., 1996; O'Keefe et al., 1997) , expression was diminished in various tumors (Hatada et al., 1996a; Thompson et al., 1996; Matsumoto et al., 2000; Oya and Schulz, 2000; Shin et al., 2000a; Schwienbacher et al., 2000) , suggesting that the diminution might be caused by disruption of epigenetic regulation and may be associated with tumorigenesis.
CDKN1C, an imprinted gene showing maternal preferential expression, is located within an imprinted region at 11p15.5 (Hatada and Mukai, 1995) . This wellknown region is divided into two domains, CDKN1C/ LIT1 and IGF2/H19 (Feinberg, 2000) . The expression of imprinted genes within these domains is regulated by an imprinting control region (ICR) specific to each domain. In IGF2/H19, the differentially methylated region (DMR) upstream of H19 is known as an ICR. As for CDKN1C/LIT1, DMR at the 5 0 CpG island of noncoding LIT1 transcript (DMR-LIT1) is a putative ICR (Figure 1a ). DMR-LIT1 is normally methylated on the maternal allele and unmethylated on the paternal Mitsuya et al., 1999; Smilinich et al., 1999) . DMR-LIT1 is only a gametic methylated region, methylated in oocyte, within Cdkn1c/Lit1 (Yatsuki et al., 2002) . Targeted deletion of DMR-Lit1 on the paternally inherited chromosome resulted in the derepression in cis of imprinted genes, including Cdkn1c (Fitzpatrick et al., 2002) . Targeted deletion of human DMR-LIT1 using microcell hybrids also showed reactivation of CDKN1C expression (Horike et al., 2000) . These results suggested that demethylation of maternally methylated DMR-LIT1 would diminish CDKN1C expression in tumors. It had been reported that loss of maternal DMR-LIT1 methylation was common in various adult tumors (Scelfo et al., 2002) , and the abnormal imprinting status of CDKN1C was correlated with loss of maternal methylation of DMR-LIT1 in hepatocarcinoma (Schwienbacher et al., 2000) .
However, it is well known that hypermethylation of the promoter contributes to silencing of tumor suppressor genes in human cancer (Jones and Laird, 1999; Baylin et al., 2001) . It was recently reported that in several tumors, CDKN1C silencing was associated with dense methylation of the region around the transcription start site (Shin et al., 2000b; Kikuchi et al., 2002; Li et al., 2002) . Thus, it has been controversial whether reduction of CDKN1C expression in cancer is caused by disruption of an imprinting control mechanism or by its own promoter hypermethylation.
In all eukaryotes, the covalent modification of histone N-terminal tails is important in the regulation of transcription, mitosis, and heterochromatin formation (Strahl and Allis, 2000; Jenuwein and Allis, 2001 ). H3K9 methylation was associated with the formation of stably silenced chromatin in mammals (Lachner et al., 2001) . Histone acetylations and histone H3 lysine 4 (H3K4) methylation changed the chromatin structure to increase accessibility to transcriptional factors and correlated with transcriptional activity, respectively (Strahl et al., 1999; Strahl and Allis, 2000) . To date, histone modifications at several imprinted loci, such as SNRPN, IGF2/H19, Igf2r, and U2af1-rs1, have been examined. Recently, we clarified histone modification status at DMR-LIT1 in mouse and human tissues . However, in human cancer, the modification at DMR-LIT1 and CDKN1C promoter has not yet been examined.
Here, we describe the relationships between CDKN1C expression and epigenetic factors; CpG methylation at DMR-LIT1 and CDKN1C promoter, and histone modifications at those loci. Our results suggest that diminished expression of CDKN1C due to disruption of imprinting regulation caused by loss of CpG and H3K9 methylation at DMR-LIT1 is involved in esophageal cancer.
Results
CDKN1C expression is diminished in esophageal cancer cell lines
We analysed 17 esophageal cancer cell lines (#1-17, Table 1 ). First, the expression level of the CDKN1C gene was quantified with ribonuclease protection assay (RPA) and real-time RT-PCR normalized with that of a housekeeping hydroxymethylbilane synthase gene Data from all cell lines were plotted in a graph. White triangles were #12-14 (asterisked in (e) Figure 1b ). Among the cell lines, expression of CDKN1C varied from 0.006 to 0.597 by RPA, and from 0.01 to 1.46 by RT-PCR. Values from both experiments were closely correlated (Spearman's rank-correlation coefficient r ¼ 0.912, P ¼ 0.0003), indicating correct evaluation of CDKN1C expression. Second, the quantity of DMR-LIT1 CpG methylation status was determined by Southern blotting with BamHI and methylation-sensitive NotI (Figure 1c) . Detection of only a 1.8 kb band by NotC control probe indicated complete digestion by NotI. The average CpG methylation index (MI) at DMR-LIT1 obtained from two normal placentae and seven individual peripheral blood cells was 51.075.4% (Figure 1c and data not shown). This was consistent with the finding that DMR-LIT1 is methylated differentially Mitsuya et al., 1999; Smilinich et al., 1999) . The MI of cancer cell lines varied from 0.0 to 100%. Since four lines unexpectedly showed only methylated bands, MI was confirmed by quantitative combined bisulfite restriction analysis (COBRA), employing the hot-stop method ( Figure 1d ). Next, we investigated heterozygosity of 11p15.5 using 10 polymorphic loci. The copy number of 11p15.5 was calculated by band intensity obtained from Southern blotting (Table 1) . Since no informative line for a polymorphism of CDKN1C was found, we were not able to investigate the allelic expression of the gene. We found that 11 lines sustained two copies of 11p15.5, and the other six lines had only one copy. Among 11 cell lines harboring two copies, three (#1-3) showed normal CpG methylation of DMR-LIT1, indicating maintained imprinting of the CDKN1C/LIT1 domain. The average CDKN1C expression of the three was 0.3170.10 by RPA and 0.8570.17 by RT-PCR. Of 17 lines (59%, #4-13), 10 showed lower expression of CDKN1C than the imprinting maintained lines (average -2 s.d., only #7 by RPA was lower than average -1 s.d.), whereas four (#14-17) showed the same or higher expression.
CDKN1C expression is closely correlated with CpG methylation of DMR-LIT1
To investigate whether CDKN1C expression was regulated by DMR-LIT1, an ICR of the CDKN1C/LIT1 imprinted domain, we statistically investigated a correlation between CDKN1C expression and DMR-LIT1 MI. All cell lines except three (#12-14) showed close correlation between CDKN1C expression by RPA and DMR-LIT1 MI (Figure 1e and f, r ¼ 0.832, P ¼ 0.0027). Close correlation was also seen using RT-PCR data (r ¼ 0.851, P ¼ 0.0022). Cell lines #12-14 showed apparent inconsistency between the two parameters ( Figure 1e ). Using data from nine lines harboring two copies of 11p15.5 (#1-3, 8-11, 16, 17) , DMR-LIT1 MI still showed positive correlation with CDKN1C expression (r ¼ 0.831, P ¼ 0.0188 by RPA, r ¼ 0.881, P ¼ 0.0127 by RT-PCR). Thus, it was strongly suggested that CDKN1C expression was controlled by DMR-LIT1 in the majority of human cancer cell lines investigated. and CDKN1C promoter region 2 were analysed by Southern blotting, and MI of regions 1, 3, 4, and 5 was analysed by hot-stop COBRA. In all, 10 polymorphic loci within 11p15.5 were analysed to examine heterozygosity. Copy number of 11p15.5 was determined by polymorphic marker analyses and by measurement of Southern blotting band intensity. hetero: heterozygous for at least one of polymorphic loci; NI: not informative CDKN1C silencing associated with DMR-LIT1 in cancer H Soejima et al
CDKN1C expression is not correlated with CpG methylation of its own promoter
To investigate whether CDKN1C expression might be correlated with CpG methylation of CDKN1C promoter itself, we quantified the MI of the CDKN1C promoter ( Figure 2a , showed low to high MI of either region 4 or 5. We also statistically investigated a correlation between CDKN1C expression and the MI of each region in CDKN1C promoter. In all cell lines, CDKN1C expression, from both RPA and RT-PCR, was not correlated with MI of any region (Figure 2b ). There was still no correlation when #12-14 were excluded (data not shown).
Histone modifications at DMR-LIT1 and CDKN1C promoter
To investigate histone modifications at the DMR-LIT1 and CDKN1C promoter in cancer cells, we performed ChIP assay with three primer sets for each gene ( Figure  3a and b) . We used three cell lines -#2, #8, and #9. In these cells, LIT1 expression was also quantified with real-time RT-PCR. The results of the control loci, GAPD and the chromosome 16 centromere region, indicated successful ChIP procedures ( Figure 3c ). All histone modifications were detected in #2. Since #2 showed normal MI at DMR-LIT1, acetylations and H3K4 methylation at DMR-LIT1 were on the paternal allele and H3K9 methylation was on the maternal allele, according to our previous study (Figure 3a and d) . Cell lines #8 and #9, showing CpG unmethylation on both alleles and diminished CDKN1C expression, probably had loss of imprinting of LIT1. Acetylations and H3K4 methylation at DMR-LIT1 were apparently higher in #8 and #9, along with the decrease of MI and increase of LIT1 expression, than in #2 at all regions. By contrast, H3K9 methylation was undetectable in any region. In the CDKN1C promoter region, acetylations and H3K4 methylation were detectable in all lines. However, these were unchanged or slightly increased in #8 and #9 despite diminished CDKN1C expression. Furthermore, H3K9 methylation was barely detectable at CDKN1C promoter in any of the three lines. The results suggested that histone modifications at CDKN1C promoter were not associated with its expression. This was supported by ChIP on #12-14, showing association of LIT1 expression and histone modifications and MI at DMR-LIT1, and no association of CDKN1C expression or histone modifications at CDKN1C promoter, although CDKN1C expression was inconsistent with DMR-LIT1 MI in them (data not shown). Intriguingly, #2 showed no methylation of H3K9 in any region, although CDKN1C on the paternal allele is normally repressed by imprinting. Neither was H3K9 methylated in lymphoblastoid cells established from normal individual and BWS patients, in which DMR-LIT1 MI was maintained normally (data not shown). 
Discussion
An important finding was that in the majority of esophageal cancer cell lines investigated, the epigenetic factor correlated with CDKN1C expression was the CpG methylation status of DMR-LIT1, not that of the CDKN1C promoter itself. Furthermore, H3K9 methylation of DMR-LIT1 was closely associated with CpG methylation. Notably, approximately 36% (4/11) of lines possessing two copies of 11p15.5 showed diminished CDKN1C expression. These four lines showed complete or partial demethylation at DMR-LIT1, indicating that imprinting disruption of the CDKN1C/ LIT1 domain with loss of CpG methylation at DMR-LIT1 leads to the reduction of CDKN1C expression, which would be involved to some extent in esophageal cancers. Diaz-Meyer et al. (2003) recently reported that in BWS fibroblast cells, silencing of CDKN1C is associated with hypomethylation of DMR-LIT1, supporting our result. Previous reports, however, described the association of hypermethylation of CDKN1C promoter region with gene silencing (Shin et al., 2000b; Kikuchi et al., 2002; Li et al., 2002) , but did not examine the methylation of DMR-LIT1. Since those analysed tumors originated from other tissues, we speculated that a tissue-specific epigenetic mechanism for CDKN1C expression might be involved. CDKN1C expression of three lines (#12-14) in this study did not correlate with the CpG methylation of DMR-LIT1. Although we are not able to account for it at this point, other unknown genetic or/and epigenetic alteration(s) might occur. Or these inconsistencies might originate from abnormal methylation due to cell culture artifacts. Demethylation of DMR-LIT1 is found in approximately half of patients with BWS, known for its high incidence of embryonal tumors. CDKN1C mutation is also found in a minority of BWS. Weksberg et al. (2001) showed a higher tumor risk in patients with demethylation of DMR-LIT1 (5/35) than in CDKN1C mutation (0/5). This is supported in Lam et al. (1999) . However, in earlier data, the tumor risk of CDKN1C mutation versus DMR-LIT1 demethylation was the same (2/38 versus 6/ 123) (Weksberg et al., 2001) . In tumors without BWS, diminished expression of CDKN1C ranges from 35 to 100% in various tumors, including esophageal cancer (Hatada et al., 1996a; Thompson et al., 1996; Matsumoto et al., 2000; Oya and Schulz, 2000; Schwienbacher et al., 2000; Shin et al., 2000a) . Reasons could include demethylation of maternal DMR-LIT1 (imprinting disruption), as mentioned here; loss of maternal allele; and other epigenetic mechanism(s).
In human and mouse, maternal DMR-LIT1 with CpG methylation is associated with H3K9 methylation and that paternal DMR-LIT1 is not. BWS patients with loss of CpG methylation at DMR-LIT1 showed a loss of H3K9 methylation . These findings, in conjunction with our results, indicate that DMR-LIT1 is an ICR for CDKN1C/LIT1 domain and regulates the expression of neighboring imprinted genes, including CDKN1C, within the domain in humans as well as in mice. The findings also suggested that H3K9 methylation is involved in the maintenance of imprinting. Paternal DMR-LIT1 without CpG and H3K9 methylation silences neighboring imprinted genes, normally active on the maternal allele. Thus, the imprinting disruption with loss of CpG and H3K9 methylation causes epigenotype change from maternal to paternal, reducing CDKN1C expression, and is probably involved in cancer and BWS.
It has been reported that DMR-LIT1 are an orientation-independent silencer (Du et al., 2003; ManciniDiNardo et al., 2003; Thakur et al., 2003) . Thakur et al. (2003) proposed that a repressive chromatin structure established at DMR-LIT1 might propagate bidirectionally along the DNA to inactivate neighboring genes. Since LIT1 is an antisense noncoding transcript, the establishment and propagation of a repressive chromatin structure might be similar to that of Igf2r ICR, which contains Air, an antisense noncoding transcript of Igf2r (Sleutels et al., 2002) . H3K9 methylation was, however, barely detectable at CDKN1C promoter in the cancer cell lines and undetectable in cells with normal MI, suggesting that H3K9 methylation is not involved in CDKN1C repression on the paternal epigenotype chromosome. Since the human CDKN1C sequence was also reported to be an orientation-independent silencer (Du et al., 2003) and was not differentially methylated, CDKN1C may be synergistically repressed by the imprinting suppression and its own silencing activity on the paternal allele. In addition, methylated DMR-LIT1 on the maternal allele may function as a repressor of the CDKN1C silencer, leading to maternal expression. Further studies to clarify the intricate imprinting regulation mechanism will help in understanding imprinting-associated human diseases, such as cancer and BWS. KYSE 140, KYSE 170, KYSE 350, KYSE 410, KYSE510, KYSE 960 (Shimada et al., 1992) , HARA, TE9, and TE10 were grown in Dulbecco's modified Eagle's medium with 10% FCS. KE3, KE4, YES1, YES 2, YES3, YES4, YES5, YES6, and lymphoblastoid cells established from a normal individual and BWS patients were grown in RPMI-1640 with 10% FCS. Growing cells with 70% confluence were harvested for analyses.
Materials and methods
Cell lines
Quantitative analysis of gene expression
To generate probes for RPA, RT-PCR products for CDKN1C and HMBS genes were cloned into pT7Blue T-vector (Novagen). After confirming insert sequences and directions, plasmid DNAs were prepared and linearized. To make antisense riboprobes, linearized plasmid DNAs, harboring the inserts with antisense direction, were transcribed by T7 RNA polymerase with [a- 32 P]CTP. The positive control RNAs were generated from plasmids harboring sense-directed inserts without radioisotope. Total RNAs (50 mg) were simultaneously hybridised with the two antisense riboprobes at 601C, and then digested with RNase T1. Protected bands, 201 bp for CDKN1C and 255 bp for HMBS, were analysed by electrophoresis on denaturing gel. Band intensity was measured with CDKN1C silencing associated with DMR-LIT1 in cancer H Soejima et al a BAS 2000 bioimaging analyzer (Fujifilm, Japan). For quantitative real-time RT-PCR, total RNA (500 ng) was treated with RNase-free DNaseI (Roche, Germany) and reverse-transcribed with ReverTra Ace reverse transcriptase (Toyobo, Japan) and random primers (Takara, Japan). Quantitative real-time RT-PCR was performed in triplicate with the FastStart DNA Master CYBR Green I on LightCyclert system (Roche, Germany) according to the manufacturer's protocol. The expression of CDKN1C was normalized with that of HMBS.
Methylation analysis
Quantity of DMR-LIT1 methylation status was determined by Southern blotting. Genomic DNA (3 mg) was digested with BamHI and methylation-sensitive NotI. The blot was probed as described previously . To confirm complete digestion, the blot was reprobed with NotC probe, which detected an internal control locus containing a known unmethylated NotI site in CpG island (Bliek et al., 2001 ; Accession number: NT_011519). CDKN1C promoter region 2 was also analysed by Southern blotting. Genomic DNA was digested with ScaI and methylation-sensitive SacII, then hybridized with the probe shown in Figure 2a . Regions 1, 3, 4, and 5 were analysed by quantitative COBRA with the hotstop method to exclude the problem of heteroduplex formation skewing the results of restriction endonuclease digestion of PCR products (Xiong and Laird, 1997; Uejima et al., 2000) . After bisulfite-treated DNA was amplified with a number of PCR cycles sufficient to detect a product, an end-labeled primer was added, and then the PCR step was performed only once. The PCR product was digested with the appropriate restriction endonuclease (Figure 2) . Methylation of DMR-LIT1 was also examined by hot-stop COBRA with AccII. Band intensity obtained from Southern blotting and hot-stop COBRA was measured with a BAS 2000 (Fujifilm, Japan). The MI was calculated by (intensity of methylated band/(intensity of methylated band þ intensity of unmethylated band)). Analyses of polymorphism and 11p15.5. copy number Heterozygosity of 11p15.5 was examined using the following polymorphic loci: the microsatellites D11S1997, D11S2362, and D11S4088, and intragenic polymorphisms in ORCTL2S, KCNQ1DN, CDKN1C, LIT1, tyrosine hydroxylase, IGF2, and H19 (primer sequences and PCR conditions are available on request to corresponding author). The copy number of 11p15.5 was calculated by band intensity obtained from Southern blotting. Genomic DNA (2 mg) from cancer cell lines was digested with BamHI. To make the standard curve, 1, 2, 3, and 4 mg of normal genomic DNAs were also digested. The blot was probed as described previously , then the intensity of each cell line was plotted to the standard curve to determine the copy number.
ChIP
We used four kinds of antibody -antiacetylated histone H3, antiacetylated histone H4, antidimethylated histone H3K4 (Upstate Biotechnology), and monoclonal antidimethylated histone H3K9 (Nakagawachi et al., 2003) . Chromatin was prepared from 1.0 Â 10 6 cells and sonicated to an average size of B0.5 kb, then immunoprecipitated with each antibody. Protein A-and G-sepharose beads were used to collect the immunoprecipitated complex with antibodies of H3Ac, H4Ac, and H3meK4 and with monoclonal anti-H3meK9, respectively. DNA recovered from immunoprecipitated complex was subjected to PCR. To ensure quantification of PCR amplification, each reaction was initially set up at various amplification cycle numbers, and the logarithmic amplification phase was detected. As final PCR conditions, we determined 31 cycles for all regions, except for 33 cycles at LC1 region. PCR products were quantified with NIH Image 1.62, and fold enrichment in each immunoprecipitation was determined by the ratio to input DNA (total chromatin). GAPD and the centromere region of chromosome 16 were amplified as described previously . ChIP and PCR for each ChIP were performed at least in duplicate, respectively.
Primers and PCR conditions
Primer sequences and PCR conditions are shown in Table 2 .
Statistics
Statistical analyses were performed with Spearman's rankcorrelation test. Po0.05 was thought to be significant.
